A.V. Pastor

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes et al. · Journal of Clinical Oncology · 2024 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study

M.R. Dzienis, J.E. Cundom, Christian Sebastian Fuentes et al. · Annals of Oncology · 2022 · 21 citations

Medicine, Oncology, Pharmacology +14